Oral anticoagulant therapy for patients with atrial fibrillation - an update

Thrombosis Research

Volumn 123, Issue SUPPL. 1, 2008, Pages

  Hylek, Elaine M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; MONOTHERAPY; PRIORITY JOURNAL; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; WARFARIN;

EID: 55249096656     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.016     Document Type: Article

References (24)

1. Miyasaka Y., Barnes M.E., Gersh B.J., Cha S.S., Bailey K.R., Abhayaratna W.P., Seward J.B., and Tsang T.S.M. Secular Trends in Incidence of Atrial Fibrillation in Olmstead County, Minnesota, 1980-2000, and Implications on the Projections for Future Prevalence. Circulation 114 (2006) 119-125
2. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 8 (1991) 983-988
3. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation 98 10 (1998) 946-952
4. Mackay J., and Mensah G.A. The Atlas of Heart Disease and Stroke (2004), World Health Organization, Geneva, Switzerland
5. American Heart Association. Heart Disease and Stroke Statistics-2006 Update. Circulation 113 6 (2006) e85-e151
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 13 (1994) 1449-1457
7. Waldo A.L., Becker R.C., Tapson V.F., and Colgan K.J. Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. J Am Coll Cardiol 46 9 (2005) 1729-1736
8. Birman-Deych E.R.M., Nilasena D.S., and Gage B.F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 37 4 (2006) 1070-1074
9. Johnston J.A., Cluxton Jr. R.J., Heaton P.C., Guo J.J., Moomaw C.J., and Eckman M.H. Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation. Arch Intern Med 163 14 (2003) 1705-1710
10. Davis S.M., Broderick J., Hennerici M., Brun N.C., Diringer M.N., Mayer S.A., Begtrup K., Steiner T., and for the Recombinant Activated Factor VIIIHTI. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66 (2006) 1175-1181
11. Go A.S., Hylek E.M., Chang Y., Phillips K.A., Henault L.E., Capra A.M., Jensvold N.G., Selby J.V., and Singer D.E. Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?. JAMA 290 20 (2003) 2685-2692
12. The Atrial Fibrillation Follow-up Investigation of Rhythm Management I. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med 347 23 (2002) 1825-1833
13. Hylek E.M., Evans-Molina C., Shea C., Henault L.E., and Regan S. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation. Circulation 115 21 (2007) 2689-2696
14. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E.M. The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 204S-233S
15. Garcia D., Regan S., Crowther M., Hughes R.A., and Hylek E.M. Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population. Chest 127 6 (2005) 2049-2056
16. Hylek E.M., Regan S., Go A.S., Hughes R.A., Singer D.E., and Skates S.J. Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin. Ann Intern Med 135 6 (2001) 393-400
17. Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Capra A.M., Phillips K.A., Henault L.E., Selby J.V., and Singer D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 11 (2003) 1019-1026
18. Dentali F., Douketis J.D., Lim W., and Crowther M. Combined Aspirin-Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials. Arch Intern Med 167 2 (2007) 117-124
19. Lip G.Y., Frison L., and Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 28 6 (2007) 752-759
20. Arima H., Hart R.G., Colman S., Chalmers J., Anderon C., Rodgers A., Woodward M., MacMahon S., Neal B., and for the PROGRESS Collaborative Group. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 36 (2005) 2164-2169
21. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 285 22 (2001) 2864-2870
22. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. Circulation 114 7 (2006) 700-752
23. Mitchell G.F., Vasan R.S., Keyes M.J., Parise H., Wang T.J., Larson M.G., D'Agostino Sr. R.B., Kannel W.B., Levy D., and Benjamin E.J. Pulse Pressure and Risk of New-Onset Atrial Fibrillation. JAMA. 297 7 (2007) 709-715
24. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle M., Yusuf S., and Connolly S.J. Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis. Journal of the American College of Cardiology. 45 11 (2005) 1832-1839